Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses: 2014-2025

Historic Change in Accured Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $4.6 million.

  • Viridian Therapeutics, Inc.\DE's Change in Accured Expenses rose 18.07% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 61.13%. This contributed to the annual value of $21.6 million for FY2024, which is 331.64% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Change in Accured Expenses of $4.6 million as of Q3 2025, which was down 24.54% from $6.1 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Change in Accured Expenses ranged from a high of $11.1 million in Q4 2024 and a low of -$15.8 million during Q1 2025.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Change in Accured Expenses had a median value of $3.9 million in 2024 and averaged $2.0 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 1,610.78% in 2021, then plummeted by 1,671.03% in 2025.
  • Viridian Therapeutics, Inc.\DE's Change in Accured Expenses (Quarterly) stood at $1.6 million in 2021, then spiked by 269.25% to $6.0 million in 2022, then decreased by 19.69% to $4.8 million in 2023, then skyrocketed by 129.80% to $11.1 million in 2024, then climbed by 18.07% to $4.6 million in 2025.
  • Its Change in Accured Expenses stands at $4.6 million for Q3 2025, versus $6.1 million for Q2 2025 and -$15.8 million for Q1 2025.